Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 166,734	$ 541,835
Available for sale securities	42,168	0
Accounts receivable, net of allowances of approximately $6.7 million and $2.9 million at September 30, 2017 and December 31, 2016, respectively	7,793	22,087
Inventory, net	67,169	70,898
Prepaid expenses and other current assets	13,974	19,133
Total current assets	297,838	653,953
Fixed assets, net	18,022	30,961
Indefinite-lived intangible assets	0	253,620
Finite-lived intangible assets, net	285,965	361,601
Goodwill	255,629	255,629
Restricted cash	5,048	5,032
Contingent purchase price from sale of businesses	143,700	143,700
Other assets	778	715
Total assets	1,006,980	1,705,211
Current liabilities:
Accounts payable	11,698	28,450
Accrued expenses	81,246	88,524
Current portion of contingent purchase price	28,700	55,000
Convertible senior notes	0	53,749
Deferred revenue	7,269	18,902
Total current liabilities	128,913	244,625
Contingent purchase price	34,183	82,289
Convertible senior notes	642,655	623,584
Deferred tax liabilities	0	89,992
Other liabilities	13,174	11,705
Total liabilities	818,925	1,052,195
Equity component of currently redeemable convertible senior notes	0	1,033
Stockholders’ equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value per share, 187,500,000 authorized; 75,791,437 issued and 72,778,294 outstanding at September 30, 2017 and 73,212,545 issued and 71,019,563 outstanding at December 31, 2016	76	73
Additional paid-in capital	1,362,040	1,256,890
Treasury stock, at cost; 3,013,143 and 2,192,982 shares at September 30, 2017 and December 31, 2016, respectively	(90,016)	(50,000)
Accumulated deficit	(1,079,096)	(548,983)
Accumulated other comprehensive loss	(4,949)	(5,479)
Total The Medicines Company stockholders’ equity	188,055	652,501
Non-controlling interest in joint venture	0	(518)
Total stockholders’ equity	188,055	651,983
Total liabilities and stockholders’ equity	1,006,980	1,705,211
Product licenses, net
Current assets:
Finite-lived intangible assets, net	0	26,987
Developed product rights, net
Current assets:
Finite-lived intangible assets, net	285,965	334,614
In-process research & development
Current assets:
Indefinite-lived intangible assets	$ 0	$ 253,620